Treatment rationale and study design for the RELAY study: a multicenter, randomized, double-blind study of erlotinib with ramucirumab or placebo in patients with …
EB Garon, M Reck, L Paz-Ares, S Ponce, JC Jaime… - Clinical lung …, 2017 - Elsevier
Introduction We present the treatment rationale and study design for the RELAY study
(NCT02411448). This phase Ib/III study will assess safety, tolerability, and efficacy of the …
(NCT02411448). This phase Ib/III study will assess safety, tolerability, and efficacy of the …
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients …
EB Garon, M Reck, L Paz-Ares, S Ponce… - Clinical Lung …, 2017 - clinical-lung-cancer.com
Introduction We present the treatment rationale and study design for the RELAY study
(NCT02411448). This phase Ib/III study will assess safety, tolerability, and efficacy of the …
(NCT02411448). This phase Ib/III study will assess safety, tolerability, and efficacy of the …
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients …
EB Garon, M Reck, L Paz-Ares, S Ponce, JC Jaime… - Clinical Lung …, 2017 - infona.pl
We present the treatment rationale and study design for the RELAY study (NCT02411448).
This phase Ib/III study will assess safety, tolerability, and efficacy of the combination of …
This phase Ib/III study will assess safety, tolerability, and efficacy of the combination of …
[引用][C] Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in …
EB Garon, M Reck, L Paz-Ares, S Ponce, JC Jaime… - Clinical Lung …, 2017 - cir.nii.ac.jp
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized,
Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal …
Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal …
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients …
EB Garon, M Reck, L Paz-Ares, S Ponce… - Clinical lung …, 2017 - pubmed.ncbi.nlm.nih.gov
Introduction We present the treatment rationale and study design for the RELAY study
(NCT02411448). This phase Ib/III study will assess safety, tolerability, and efficacy of the …
(NCT02411448). This phase Ib/III study will assess safety, tolerability, and efficacy of the …
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients …
EB Garon, M Reck, L Paz-Ares, S Ponce… - Clinical Lung …, 2016 - europepmc.org
Conclusion Erlotinib with ramucirumab combination was chosen because the addition of an
antiangiogenic agent, such as ramucirumab, would further improve the efficacy of erlotinib …
antiangiogenic agent, such as ramucirumab, would further improve the efficacy of erlotinib …